1910 Genetics is integrating AI, computation and biological automation to accelerate drug discovery. The current pharmaceutical R&D model is unsustainable, taking 12 to 15 years to bring new drugs to market, costing billions of dollars and having a success rate lower than 10%. 1910 Genetics is using their proprietary machine learning platforms to circumvent these problems by shortening the timeline and reducing operational costs of drug development. Their platforms, ELVIS and ROSALYND, are being employed for novel hit discovery, hit-to-lead and lead optimization for both small molecule and protein therapeutics. 1910 Genetics’ pipeline is disease agnostic, advancing drug discovery for all major diseases.

1910 Genetics is integrating AI, computation and biological automation to accelerate drug discovery. The current pharmaceutical R&amp;D model is unsustainable, taking 12 to 15 years to bring new drugs to market, costing billions of dollars and having a success rate lower than 10%. 1910 Genetics is using their proprietary machine learning platforms to circumvent these problems by shortening the timeline and reducing operational costs of drug development. Their platforms, ELVIS and ROSALYND, are being employed for novel hit discovery, hit-to-lead and lead optimization for both small molecule and protein therapeutics. 1910 Genetics’ pipeline is disease agnostic, advancing drug discovery for all major diseases.

1910 Genetics

20n Bio is using computational biology to design novel molecules such as protein therapeutics. At the core of 20n Bio’s philosophy is their open source platform for synthetic biology. Synthetic biology involves using the blueprint of DNA to make molecules biologically and more sustainably. 20n has used their approach to invent organisms that make acetaminophen/paracetamol (APAP) by fermenting sugar. 20n achieved this by engineering an E.coli and a yeast with a gene from a mushroom and over-expression of two native genes. The entire supply of APAP can be generated from petroleum. By using deep learning and biochemistry, 20n offers their Bioreachable Service platform to help teams identify new molecules, or discover more efficient ways to reach a product.

20n Bio is using computational biology to design novel molecules such as protein therapeutics. At the core of 20n Bio’s philosophy is their open source platform for synthetic biology. Synthetic biology involves using the blueprint of DNA to make molecules biologically and more sustainably. 20n has used their approach to invent organisms that make acetaminophen/paracetamol (APAP) by fermenting sugar. 20n achieved this by engineering an E.coli and a yeast with a gene from a mushroom and over-expression of two native genes. The entire supply of APAP can be generated from petroleum. By using deep learning and biochemistry, 20n offers their Bioreachable Service platform to help teams identify new molecules, or discover more efficient ways to reach a product.

20n Bio

3DBio Therapeutics is implanting 3D-bioprinted living tissues in patients. Living tissue implants are regenerative medicines that can be built from a patient’s own healthy tissue. 3DBio is generating personalized tissue implants using their four-part technology platform including their proprietary 3D-bioprinter (GMPrint), bio-ink (ColVivo), specialized cell culture and implantable protective shells. These implants are patient-matched and patient-derived, and 3DBio’s first product, AuriNovo, is being tested in clinical trials in adults and children. AuriNovi is created from a small biopsy on the patient’s ear remnant which is then used by 3DBio to print new, normally-shaped ears. The newly created ear is implanted into the patient clinically.

3DBio Therapeutics is implanting 3D-bioprinted living tissues in patients. Living tissue implants are regenerative medicines that can be built from a patient’s own healthy tissue. 3DBio is generating personalized tissue implants using their four-part technology platform including their proprietary 3D-bioprinter (GMPrint), bio-ink (ColVivo), specialized cell culture and implantable protective shells. These implants are patient-matched and patient-derived, and 3DBio’s first product, AuriNovo, is being tested in clinical trials in adults and children. AuriNovi is created from a small biopsy on the patient’s ear remnant which is then used by 3DBio to print new, normally-shaped ears. The newly created ear is implanted into the patient clinically.

3DBio Therapeutics

3T Biosciences is identifying novel targets for the treatment of solid tumors and other immune-mediated diseases. Current treatment options for solid tumors often have limited or negligible efficacy.  3T is understanding how the immune system recognises, targets and destroys cancer cells to develop novel immunotherapies. To develop immunotherapies, 3T is using their proprietary, novel technology called 3T-TRACE (T cell receptor antigen and cross-reactivity engine) to identify novel targets and therapeutically active T cell receptors (TCRs) and TCR mimetics (TCRm). 3T-TRACE employs machine learning and high-diversity target libraries to create highly specific, safe and more effective cancer treatments. 

3T Biosciences is identifying novel targets for the treatment of solid tumors and other immune-mediated diseases. Current treatment options for solid tumors often have limited or negligible efficacy. 3T is understanding how the immune system recognises, targets and destroys cancer cells to develop novel immunotherapies. To develop immunotherapies, 3T is using their proprietary, novel technology called 3T-TRACE (T cell receptor antigen and cross-reactivity engine) to identify novel targets and therapeutically active T cell receptors (TCRs) and TCR mimetics (TCRm). 3T-TRACE employs machine learning and high-diversity target libraries to create highly specific, safe and more effective cancer treatments.

3T Biosciences

4D Molecular Therapeutics is designing and developing transformative gene therapies for unmet medical conditions. Adeno-associated viruses (AAVs) have great potential for targeted delivery and efficient transduction of gene therapies. 4D is using their Therapeutic Vector Evolution platform to discover custom and proprietary AAVs for specific tissues and diseases to build a diverse vector library. Selected vectors are chosen and tested in non-human primates based on their Target Vector Profile for a disease. Subsequent testing is performed in human cell and organotypic tissue assays. 4D is developing a diverse pipeline of product candidates for cardiology, pulmonology and ophthalmology with products in early clinical trials.

4D Molecular Therapeutics is designing and developing transformative gene therapies for unmet medical conditions. Adeno-associated viruses (AAVs) have great potential for targeted delivery and efficient transduction of gene therapies. 4D is using their Therapeutic Vector Evolution platform to discover custom and proprietary AAVs for specific tissues and diseases to build a diverse vector library. Selected vectors are chosen and tested in non-human primates based on their Target Vector Profile for a disease. Subsequent testing is performed in human cell and organotypic tissue assays. 4D is developing a diverse pipeline of product candidates for cardiology, pulmonology and ophthalmology with products in early clinical trials.

4D Molecular Therapeutics

64x Bio is discovering new mammalian cell lines to transform cell and gene therapy manufacturing. To develop and manufacture cell therapies, cell lines that are easy to manipulate, engineer and grow are required. 64x Bio is using their VectorSelect platform to generate highly optimized cell lines that meet the requirements for production of cell therapies. In particular, 64x Bio is enhancing the efficiency of cell lines to manufacture viral vectors that improve manufacturing capacity and reduce overall cost. This involves high-throughput genome engineering, screening technologies and 64x Bio’s proprietary genetic barcoding method that connects information of viral vector productivity back to the parent cell which produced it.

64x Bio is discovering new mammalian cell lines to transform cell and gene therapy manufacturing. To develop and manufacture cell therapies, cell lines that are easy to manipulate, engineer and grow are required. 64x Bio is using their VectorSelect platform to generate highly optimized cell lines that meet the requirements for production of cell therapies. In particular, 64x Bio is enhancing the efficiency of cell lines to manufacture viral vectors that improve manufacturing capacity and reduce overall cost. This involves high-throughput genome engineering, screening technologies and 64x Bio’s proprietary genetic barcoding method that connects information of viral vector productivity back to the parent cell which produced it.

64x Bio

8Biomed is developing oxygen-based therapies to save and sustain lives. Oxygen is essential to all tissues and organs to survive. Within the body, oxygen is most efficiently transported by hemoglobin in the blood. However, oxygen can come under short supply during first responses to traumatic blood loss, organ transplants and conditions such as anemia and ischemia. 8Biomed has created a product intended to supply oxygen similarly to how blood supplies it. 8Biomed’s product works at the molecular scale and is derived from bovine blood through a process that yields highly-purified hemoglobin. The highly scalable purification of hemoglobin is then incorporated into 8Biomed’s product and can then be used with any blood type. Currently the product is awaiting completion and FDA-approval. 

8Biomed is developing oxygen-based therapies to save and sustain lives. Oxygen is essential to all tissues and organs to survive. Within the body, oxygen is most efficiently transported by hemoglobin in the blood. However, oxygen can come under short supply during first responses to traumatic blood loss, organ transplants and conditions such as anemia and ischemia. 8Biomed has created a product intended to supply oxygen similarly to how blood supplies it. 8Biomed’s product works at the molecular scale and is derived from bovine blood through a process that yields highly-purified hemoglobin. The highly scalable purification of hemoglobin is then incorporated into 8Biomed’s product and can then be used with any blood type. Currently the product is awaiting completion and FDA-approval.

8Biomed

A-Alpha Bio is accelerating drug discovery by providing cell-based tools of protein interactions. Protein interactions govern all cellular processes and are therefore linked with disease.  However, while predictive tools are now available for an individual protein structure, understanding protein interactions requires time-consuming experimentation. A-Alpha is circumventing this by generating high-quality protein-protein interaction data by measuring millions of protein-protein interactions at a time using AlphaSeq. AlphaSeq combines yeast two-hybrid technology with DNA barcodes to read out high-affinity interactions. This approach can be used to discover effective antibodies and degradable neo-substrates, engineer protein interfaces, and fuel predictive machine learning models. 

A-Alpha Bio is accelerating drug discovery by providing cell-based tools of protein interactions. Protein interactions govern all cellular processes and are therefore linked with disease. However, while predictive tools are now available for an individual protein structure, understanding protein interactions requires time-consuming experimentation. A-Alpha is circumventing this by generating high-quality protein-protein interaction data by measuring millions of protein-protein interactions at a time using AlphaSeq. AlphaSeq combines yeast two-hybrid technology with DNA barcodes to read out high-affinity interactions. This approach can be used to discover effective antibodies and degradable neo-substrates, engineer protein interfaces, and fuel predictive machine learning models.

A-Alpha Bio

A2 Biotherapeutics is designing novel cell therapies to treat serious illnesses. Therapeutics to treat cancers depend on methods to distinguish tumors from normal cells. A2 Bio is using their proprietary Tmod platform to innovate new treatments for solid tumors involving the immune system. The platform integrates multiple signals, overcoming conventional single-target therapies, and exploits tumor-specific vulnerabilities. The Tmod platform is robustly different from other cell therapy systems due to its tumor precision and efficacy by incorporating two receptors, an activator and a blocker, to modulate the immune system. As their platform is modular, A2 Bio is building a broad pipeline of both autologous and allogeneic cell therapies for many unexploited tumor targets. 

A2 Biotherapeutics is designing novel cell therapies to treat serious illnesses. Therapeutics to treat cancers depend on methods to distinguish tumors from normal cells. A2 Bio is using their proprietary Tmod platform to innovate new treatments for solid tumors involving the immune system. The platform integrates multiple signals, overcoming conventional single-target therapies, and exploits tumor-specific vulnerabilities. The Tmod platform is robustly different from other cell therapy systems due to its tumor precision and efficacy by incorporating two receptors, an activator and a blocker, to modulate the immune system. As their platform is modular, A2 Bio is building a broad pipeline of both autologous and allogeneic cell therapies for many unexploited tumor targets.

A2 Biotherapeutics

AavantiBio is using gene transfer and gene editing to develop new therapies to treat genetic diseases. Precision genetic medicine technologies have the potential to treat or cure many serious genetic diseases with significant unmet need. Beginning with Friedreich’s ataxia, AavantiBio is building a platform combining their technology with chemistry and manufacturing to create many therapeutic modalities. Critical to AavantiBio’s approach is transient immunomodulation, to prevent immune responses to adeno-associated viruses that deliver the genetic payload. AavantiBio is using comprehensive preclinical and clinical data to support their immunomodulation method. Currently, AavantiBio’s pipeline is in preclinical stages with promising efficacy and safety in mice, rats and non-human primates.

AavantiBio is using gene transfer and gene editing to develop new therapies to treat genetic diseases. Precision genetic medicine technologies have the potential to treat or cure many serious genetic diseases with significant unmet need. Beginning with Friedreich’s ataxia, AavantiBio is building a platform combining their technology with chemistry and manufacturing to create many therapeutic modalities. Critical to AavantiBio’s approach is transient immunomodulation, to prevent immune responses to adeno-associated viruses that deliver the genetic payload. AavantiBio is using comprehensive preclinical and clinical data to support their immunomodulation method. Currently, AavantiBio’s pipeline is in preclinical stages with promising efficacy and safety in mice, rats and non-human primates.

AavantiBio

AB Studio is enhancing the potential and scalability of antibody-based therapeutics. There are many different types of antibodies that vary by target antigen, size and functionality. AB Studio is developing complex antibodies with enhanced efficacy, safety, and manufacturability features that have potential applications for treatment of cancer and infectious diseases. AB Studio depends upon computer-aided antibody design (CAAD) for therapeutic antibody discovery, lead selection, engineering, humanization and optimization. Antibodies made by AB Studio have been used in a variety of cases from developing tri-specific antibodies for COVID-19 to the creation of novel “imbalanced” bi-specific antibodies. 

AB Studio is enhancing the potential and scalability of antibody-based therapeutics. There are many different types of antibodies that vary by target antigen, size and functionality. AB Studio is developing complex antibodies with enhanced efficacy, safety, and manufacturability features that have potential applications for treatment of cancer and infectious diseases. AB Studio depends upon computer-aided antibody design (CAAD) for therapeutic antibody discovery, lead selection, engineering, humanization and optimization. Antibodies made by AB Studio have been used in a variety of cases from developing tri-specific antibodies for COVID-19 to the creation of novel “imbalanced” bi-specific antibodies.

AB Studio

Abalone Bio is developing antibody drugs that target receptors on the surface of cells to treat diseases. G-protein coupled receptors (GPCRs) are important for cellular health and frequently get disrupted in disease, yet many remain undruggable by small molecules. Antibodies are also limited to only blocking, not activating, GPCRs. Abalone is changing this by finding both activating or inhibiting bioactive antibodies that target GPCRs. To discover these antibodies, Abalone is combining engineered living cells with data-driven computation, which is compatible with different types of antibodies. Abalone’s first therapeutic focus is immune system regulators that cause inflammatory diseases and cancer.

Abalone Bio is developing antibody drugs that target receptors on the surface of cells to treat diseases. G-protein coupled receptors (GPCRs) are important for cellular health and frequently get disrupted in disease, yet many remain undruggable by small molecules. Antibodies are also limited to only blocking, not activating, GPCRs. Abalone is changing this by finding both activating or inhibiting bioactive antibodies that target GPCRs. To discover these antibodies, Abalone is combining engineered living cells with data-driven computation, which is compatible with different types of antibodies. Abalone’s first therapeutic focus is immune system regulators that cause inflammatory diseases and cancer.

Abalone Bio

Abata Therapeutics is understanding the biology of T cells to create therapies for autoimmune diseases. Regulatory T cells (Tregs) are a critical component of the immune system that act to suppress the immune response preventing autoimmunity. Abata is using this knowledge to engineer Tregs as targeted therapies that stop immune-mediated destruction of normal cells and restore homeostasis. Treg engineering involves expression of a T cell receptor that recognizes a tissue-restricted antigen, to selectively target the therapy to the site of disease for a robust response. In addition, engineered Tregs are optimized for durability allowing the effects of a single dose to last years. Abata has initial programs for multiple sclerosis and Type 1 diabetes.

Abata Therapeutics is understanding the biology of T cells to create therapies for autoimmune diseases. Regulatory T cells (Tregs) are a critical component of the immune system that act to suppress the immune response preventing autoimmunity. Abata is using this knowledge to engineer Tregs as targeted therapies that stop immune-mediated destruction of normal cells and restore homeostasis. Treg engineering involves expression of a T cell receptor that recognizes a tissue-restricted antigen, to selectively target the therapy to the site of disease for a robust response. In addition, engineered Tregs are optimized for durability allowing the effects of a single dose to last years. Abata has initial programs for multiple sclerosis and Type 1 diabetes.

Abata Therapeutics

Abeona Therapeutics is developing cell and gene therapies for patients with serious diseases. Delivery of gene therapies to the desired tissue without causing an immune response is important for their success. Abeona is using their next-generation adeno-associated viruses (AAVs) to selectively deliver genetic payloads to the central nervous system, lungs, eyes, muscle, liver and other tissues. Abeona’s AAVs are non-replicating and have shown potential to evade immune responses generated by exposure to naturally-occuring AAV vectors. Abeona is applying their AAV technology for several diseases with therapies already in clinical trials. This includes EB-101, in Phase III trials for patients with Epidermolysis Bullosa and other undisclosed targets in preclinical phases.

Abeona Therapeutics is developing cell and gene therapies for patients with serious diseases. Delivery of gene therapies to the desired tissue without causing an immune response is important for their success. Abeona is using their next-generation adeno-associated viruses (AAVs) to selectively deliver genetic payloads to the central nervous system, lungs, eyes, muscle, liver and other tissues. Abeona’s AAVs are non-replicating and have shown potential to evade immune responses generated by exposure to naturally-occuring AAV vectors. Abeona is applying their AAV technology for several diseases with therapies already in clinical trials. This includes EB-101, in Phase III trials for patients with Epidermolysis Bullosa and other undisclosed targets in preclinical phases.

Abeona Therapeutics

Abintus Bio

Abiosciences

Absci

Accelevir Diagnostics

Accent Therapeutics

ACELYRIN

Acepodia

Achieve Life Sciences

Acrivon Therapeutics

Acrotech Biopharma

Acutis Diagnostics

Adagio Therapeutics

Adaptive Phage Therapeutics

Adcentrx Therapeutics

Adicet Bio

Claim company profile to add description to this page.

Claim company profile to add description to this page.

Aditum Bio

adMare BioInnovations

Admera Health

Adverum Biotechnologies is creating one-time gene therapies for patients with ocular and rare diseases. These gene therapies provide durable expression of therapeutic proteins that are lacking in diseased patients. To identify effective vectors to deliver the gene therapies, Adverum is using multi-step directed evolution that screens millions of different Adeno-associated viruses’ (AAVs) capsid genes for novel properties such as cell type specificity. Following novel vector discovery, selected optimized AAVs can be produced using Adverum’s highly scalable manufacturing process. Adverum is advancing a pipeline of gene therapies for ocular diseases such as ADVM-022 for age-related macular degeneration which has entered clinical trials.

Adverum Biotechnologies is creating one-time gene therapies for patients with ocular and rare diseases. These gene therapies provide durable expression of therapeutic proteins that are lacking in diseased patients. To identify effective vectors to deliver the gene therapies, Adverum is using multi-step directed evolution that screens millions of different Adeno-associated viruses’ (AAVs) capsid genes for novel properties such as cell type specificity. Following novel vector discovery, selected optimized AAVs can be produced using Adverum’s highly scalable manufacturing process. Adverum is advancing a pipeline of gene therapies for ocular diseases such as ADVM-022 for age-related macular degeneration which has entered clinical trials.

Adverum Biotechnologies

adyn

Aeglea BioTherapeutics

Aether Bio is repurposing biologics to create new compounds. Enzymes are proteins that catalyze a variety of biochemical reactions, often at lower temperatures and higher yields than chemical production. Aether is using their platform to rapidly engineer enzymes to manufacture complex and novel products at reduced cost and time. The platform involves searching trillions of enzymes within the protein sequence space to find novel biocatalysts - by mapping the sequence space, Aether can make a searchable index. Aether’s proprietary hardware and automation enables experiments to be massively parallelized which allows Aether to build a large database for further exploration. Aether sees synthetic biology as the key approach to build the future, with automation and enzymes as the catalyst.

Aether Bio is repurposing biologics to create new compounds. Enzymes are proteins that catalyze a variety of biochemical reactions, often at lower temperatures and higher yields than chemical production. Aether is using their platform to rapidly engineer enzymes to manufacture complex and novel products at reduced cost and time. The platform involves searching trillions of enzymes within the protein sequence space to find novel biocatalysts - by mapping the sequence space, Aether can make a searchable index. Aether’s proprietary hardware and automation enables experiments to be massively parallelized which allows Aether to build a large database for further exploration. Aether sees synthetic biology as the key approach to build the future, with automation and enzymes as the catalyst.

Aether Bio

Affini-T Therapeutics is using the power of T cells to develop therapies for solid tumor cancers. T cells exhibit a cytotoxic response against tumor cells; however, T cells are repressed by the tumor cells in many cancers. Affini-T is using synthetic biology and gene editing to engineer TCR T cell therapies to target oncogenic driver mutations that cause tumors by increasing their activity. Both CD8+ and CD4+ are engineered by Affini-T to further enhance the cytotoxic response and sustained killing of tumor cells as well as to persist longer in the tumor microenvironment. With their discovery platform, Affini-T is building many oncogenic driver programs including KRAS G12V and mutant p53 that are in early development.

Affini-T Therapeutics is using the power of T cells to develop therapies for solid tumor cancers. T cells exhibit a cytotoxic response against tumor cells; however, T cells are repressed by the tumor cells in many cancers. Affini-T is using synthetic biology and gene editing to engineer TCR T cell therapies to target oncogenic driver mutations that cause tumors by increasing their activity. Both CD8+ and CD4+ are engineered by Affini-T to further enhance the cytotoxic response and sustained killing of tumor cells as well as to persist longer in the tumor microenvironment. With their discovery platform, Affini-T is building many oncogenic driver programs including KRAS G12V and mutant p53 that are in early development.

Affini-T Therapeutics

Affinia Therapeutics is enhancing gene therapies by expanding the potential of adeno-associated viruses (AAVs). AAVs are the vectors that target cells and deliver gene therapies. Affinia is using their Affinia Rationally-designed Therapies (ART) platform to improve the efficacy, safety, and manufacturability of AAVs for gene therapies. This involves re-engineering AAVs with improved tissue targeting, finding novel promoters to control gene expression levels, and new cell lines and transfection agents to enhance quality, yields, and scalability. Affinia’s current pipeline is focused on nervous system diseases, including cancers affecting the brain. These diseases are difficult to target due to the blood brain barrier, which Affinia hopes their approach will overcome.

Affinia Therapeutics is enhancing gene therapies by expanding the potential of adeno-associated viruses (AAVs). AAVs are the vectors that target cells and deliver gene therapies. Affinia is using their Affinia Rationally-designed Therapies (ART) platform to improve the efficacy, safety, and manufacturability of AAVs for gene therapies. This involves re-engineering AAVs with improved tissue targeting, finding novel promoters to control gene expression levels, and new cell lines and transfection agents to enhance quality, yields, and scalability. Affinia’s current pipeline is focused on nervous system diseases, including cancers affecting the brain. These diseases are difficult to target due to the blood brain barrier, which Affinia hopes their approach will overcome.

Affinia Therapeutics

Affinivax is developing a next-generation approach in vaccine technologies. The Centers for Disease Control and Prevention estimates that 4% of patients will contract a healthcare-associated infection each year due to antimicrobial resistance. Affinivax is addressing antimicrobial resistance with their patented technology platform called the Multiple Antigen Presentation System (MAPSTM) to develop several vaccines. The MAPSTM platform simplifies vaccine design and selects for key immunogenic epitopes to induce robust immune protection in a single vaccine.

The novel vaccines designed by Affinivax are to be tested against challenging infectious diseases. AFX3772, their lead vaccine candidate for Streptococcus pneumoniae, is expected to be tested in Phase 3 clinical trials this year.

Affinivax is developing a next-generation approach in vaccine technologies. The Centers for Disease Control and Prevention estimates that 4% of patients will contract a healthcare-associated infection each year due to antimicrobial resistance. Affinivax is addressing antimicrobial resistance with their patented technology platform called the Multiple Antigen Presentation System (MAPSTM) to develop several vaccines. The MAPSTM platform simplifies vaccine design and selects for key immunogenic epitopes to induce robust immune protection in a single vaccine.
The novel vaccines designed by Affinivax are to be tested against challenging infectious diseases. AFX3772, their lead vaccine candidate for Streptococcus pneumoniae, is expected to be tested in Phase 3 clinical trials this year.

Affinivax

AgBiome

Agena Bioscience

Akero Therapeutics

Akouos is developing AAV-based gene therapies to treat hearing loss that results from mutations in genes for inner ear function. Akouos uses specialized vectors and surgical procedures to target the inner ear.

Akouos has exclusive rights to AAV vectors that were designed specifically for diseases of the inner ear, hearing, and balance. For example, the company uses a vector called Anc8OL65 that transduces sensory cells and cochlear cells with high efficiency. Akouos delivers their gene therapies via minimally invasive surgery along the sensory epithelium, where target cells of the inner ear are located. The therapies work by various mechanisms, including delivery of a healthy gene in loss-of-function mutations, delivery of RNAi, and delivery of a protein that alters a disease pathway.

Akouos is developing AAV-based gene therapies to treat hearing loss that results from mutations in genes for inner ear function. Akouos uses specialized vectors and surgical procedures to target the inner ear.
Akouos has exclusive rights to AAV vectors that were designed specifically for diseases of the inner ear, hearing, and balance. For example, the company uses a vector called Anc8OL65 that transduces sensory cells and cochlear cells with high efficiency. Akouos delivers their gene therapies via minimally invasive surgery along the sensory epithelium, where target cells of the inner ear are located. The therapies work by various mechanisms, including delivery of a healthy gene in loss-of-function mutations, delivery of RNAi, and delivery of a protein that alters a disease pathway.

Akouos

Alamar Biosciences is building a next-generation proteomic platform for plasma and liquid protein detection. Proteins present in blood samples have potential use as biomarkers for early detection and prevention of diseases, but many of these proteins are currently outside the detectable range due to their low abundance. Alamar is creating the most sensitive proteomic liquid biopsy platform that can profile thousands of proteins from microliters of blood. The fully automated platform achieves unparalleled sensitivity by using Alamar’s two breakthrough technologies: NULISA and Attobody. Together, Alamar’s platform can achieve single-digit attomolar detection, surpassing currently available technology and providing the potential to transform healthcare.

Alamar Biosciences is building a next-generation proteomic platform for plasma and liquid protein detection. Proteins present in blood samples have potential use as biomarkers for early detection and prevention of diseases, but many of these proteins are currently outside the detectable range due to their low abundance. Alamar is creating the most sensitive proteomic liquid biopsy platform that can profile thousands of proteins from microliters of blood. The fully automated platform achieves unparalleled sensitivity by using Alamar’s two breakthrough technologies: NULISA and Attobody. Together, Alamar’s platform can achieve single-digit attomolar detection, surpassing currently available technology and providing the potential to transform healthcare.

Alamar Biosciences

Alector is developing therapies for the treatment of neurodegenerative diseases. Despite the rise in the number of patients suffering with brain disorders there is still a lack of effective therapeutics. Immune cells in the brain are important for brain health. By combining antibody technology, human genetics and the latest insights in neuroscience, Alector is building a pipeline of therapeutics to harness the body’s own immune system to heal itself. This immuno-neurology strategy is analogous to current immuno-oncology approaches to activate and recruit the adaptive immune response. Through partnering with other companies such as GSK, Alector currently has many therapeutics in Phase 1-3 clinical trials for dementia and Alzheimer’s disease.

Alector is developing therapies for the treatment of neurodegenerative diseases. Despite the rise in the number of patients suffering with brain disorders there is still a lack of effective therapeutics. Immune cells in the brain are important for brain health. By combining antibody technology, human genetics and the latest insights in neuroscience, Alector is building a pipeline of therapeutics to harness the body’s own immune system to heal itself. This immuno-neurology strategy is analogous to current immuno-oncology approaches to activate and recruit the adaptive immune response. Through partnering with other companies such as GSK, Alector currently has many therapeutics in Phase 1-3 clinical trials for dementia and Alzheimer’s disease.

Alector

AlivaMab Discovery Services

Alkahest is developing treatments for neurodegenerative and age-related diseases. Many proteins that increase or decrease with age can be identified in the blood plasma. Alkahest is characterizing these proteins, known as chronokines, to create therapeutics to slow down or reverse age-related diseases. In particular, Alkahest is interested in chronokines involved in promoting restorative biological processes or pathological degenerative processes as therapeutic targets. Target identification follows the traditional pharmaceutical method, supplemented with Alkahest’s highly selected and refined plasma fractions. Using this approach, Alkahest has many product candidates in Phase 1 & 2 clinical trials.

Alkahest is developing treatments for neurodegenerative and age-related diseases. Many proteins that increase or decrease with age can be identified in the blood plasma. Alkahest is characterizing these proteins, known as chronokines, to create therapeutics to slow down or reverse age-related diseases. In particular, Alkahest is interested in chronokines involved in promoting restorative biological processes or pathological degenerative processes as therapeutic targets. Target identification follows the traditional pharmaceutical method, supplemented with Alkahest’s highly selected and refined plasma fractions. Using this approach, Alkahest has many product candidates in Phase 1 &amp; 2 clinical trials.

Alkahest

Alladapt Immunotherapeutics

Allakos is developing antibody-based therapeutics to treat allergic and inflammatory diseases. Eosinophils and mast cells, both types of immune cells, play a role in pathogenesis of many acute and chronic inflammatory diseases. Allakos is targeting receptors expressed on the surface of different immune cells with therapeutic antibodies. Allakos’ lead therapeutic target, AK002, binds a receptor on eosinophils to deplete them as they are elevated in patients with eosinophilic gastrointestinal diseases. The receptor is Siglec-8, which when activated by the antibody, induces apoptosis in eosinophils. Positive clinical activity of AK002 has already been seen and Allokos is continuing to test the drug in more eosinophil-driven diseases.

Allakos is developing antibody-based therapeutics to treat allergic and inflammatory diseases. Eosinophils and mast cells, both types of immune cells, play a role in pathogenesis of many acute and chronic inflammatory diseases. Allakos is targeting receptors expressed on the surface of different immune cells with therapeutic antibodies. Allakos’ lead therapeutic target, AK002, binds a receptor on eosinophils to deplete them as they are elevated in patients with eosinophilic gastrointestinal diseases. The receptor is Siglec-8, which when activated by the antibody, induces apoptosis in eosinophils. Positive clinical activity of AK002 has already been seen and Allokos is continuing to test the drug in more eosinophil-driven diseases.

Company, website	Founded	Location	Size	Funding
1. 1910 Genetics	2018	Boston, MA	1-50	10-50M
2. 20n Bio	2021	Philadelphia, PA	1-50	<10M
3. 3DBio Therapeutics	2014	Long Island City, NY	1-50	<10M
4. 3T Biosciences	2017	San Francisco, CA	1-50	10-100M
5. 4D Molecular Therapeutics	2013	Emeryville, CA	101-250	100-500M
6. 64x Bio	2018	San Francisco, CA	1-50	10-100M
7. 8Biomed	2018	Malvern, PA	1-50	not disclosed
8. A-Alpha Bio	2017	Seattle, WA	1-50	10-100M
9. A2 Biotherapeutics	2018	Agoura Hills, CA	51-100	100-500M
10. AavantiBio	2019	Cambridge, MA	1-50	100-500M
11. AB Studio	2017	Hayward, CA	1-50	not disclosed
12. Abalone Bio	2017	Emeryville, CA	1-50	<10M
13. Abata Therapeutics	2021	Cambridge, MA	1-50	50-100M
14. Abeona Therapeutics	2015	New York, NY	51-100	100-500M
15. Abintus Bio	2020	San Diego, CA	1-50	not disclosed
16. Abiosciences	2019	San Francisco, CA	1-50	not disclosed
17. Absci	2011	Vancouver, WA	101-250	100-500M
18. Accelevir Diagnostics	2015	Baltimore, MD	1-50	<10M
19. Accent Therapeutics	2017	Lexington, MA	1-50	100-500M
20. ACELYRIN	2020	Los Angeles, CA	1-50	100-500M
21. Acepodia	2016	Alameda, CA	1-50	100-500M
22. Achieve Life Sciences	2015	Seattle, WA	1-50	10-100M
23. Acrivon Therapeutics	2018	Cambridge, MA	1-50	100-500M
24. Acrotech Biopharma	2018	East Windsor, NJ	51-100	not disclosed
25. Acutis Diagnostics	2014	Hicksville, NY	101-250	no disclosed
26. Adagio Therapeutics	2020	Waltham, MA	51-100	100-500M
27. Adaptive Phage Therapeutics	2016	Gaithersburg, MD	1-50	10-100M
28. Adcentrx Therapeutics	2021	San Diego, CA	1-50	10-100M
29. Adicet Bio	2014	Menlo Park, CA	51-100	100-500M
30. Aditum Bio	2019	Oakland, CA	1-50	100-500M
31. adMare BioInnovations	2019	Vancouver, BC	101-250	10-100M
32. Admera Health	2014	South Plainfield, NJ	51-100	not disclosed
33. Adverum Biotechnologies	2012	Redwood City, CA	101-250	100-500M
34. adyn	2020	Seattle, WA	1-50	<10M
35. Aeglea BioTherapeutics	2013	Austin, TX	101-250	10-100M
36. Aether Bio	2017	Menlo Park, CA	1-50	not disclosed
37. Affini-T Therapeutics	2021	Watertown, MA	1-50	not disclosed
38. Affinia Therapeutics	2019	Waltham, MA	51-100	100-500M
39. Affinivax	2014	Cambridge, MA	101-250	100-500M
40. AgBiome	2012	Research Triangle Park, NC	101-250	100-500M
41. Agena Bioscience	2014	San Diego, CA	101-250	not disclosed
42. Akero Therapeutics	2017	San Francisco, CA	1-50	100-500M
43. Akouos	2016	Boston, MA	51-100	100-500M
44. Alamar Biosciences	2018	Fremont, CA	1-50	10-100M
45. Alector	2013	San Francisco, CA	101-250	100-500M
46. AlivaMab Discovery Services	2018	San Diego, CA	1-50	not disclosed
47. Alkahest	2014	San Carlos, CA	51-100	10-100M
48. Alladapt Immunotherapeutics	2018	Menlo Park, CA	1-50	10-100M
49. Allakos	2012	Redwood City, CA	101-250	100-500M
50. Allarta Life Science	2018	Hamilton, ON	1-50	<10M

Companies